Literature DB >> 1671630

Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis.

W V Epstein1, C J Henke, E H Yelin, P P Katz.   

Abstract

OBJECTIVE: To describe the course of rheumatoid arthritis over 5 years in adults and to evaluate the effect of parenterally administered gold salts on that course.
DESIGN: A prospective observational study of adults with rheumatoid arthritis. Data derived from annual interviews with patients from 1983 to 1988 and from physician surveys in 1983 and 1987.
SETTING: Rheumatology practices in the community. PATIENTS: The study began in 1982 with 822 adults who had rheumatoid arthritis and were under the care of rheumatologists.
INTERVENTIONS: Those selected by rheumatologists in the management of their patients. MEASUREMENTS: Information describing sociodemographic and clinical characteristics, course, and therapy was collected from patients and verified by physician reports. Functional status, measured by the Health Assessment Questionnaire, and the number of painful joints were used as outcome variables. Outcome variables were adjusted for age, sex, disease duration, baseline values of the outcome variable, and the use of four disease-remittive agents other than gold. MAIN
RESULTS: Multivariate repeated-measures analysis of variance showed no change in the course of rheumatoid arthritis over 5 years. The use of parenteral gold for at least 2 consecutive years at the start of the observation period produced, on average, no change in the course over 5 years in the two outcome variables.
CONCLUSION: In our study of a community-based population of adults with rheumatoid arthritis who were under the care of community rheumatologists, we found that there was, on average, no statistically significant change in function or number of painful joints between 1983 and 1988. Patients receiving parenteral gold therapy for at least 2 consecutive years did not show a statistically significant difference in outcome when compared with those not receiving such therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671630     DOI: 10.7326/0003-4819-114-6-437

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

1.  A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis.

Authors:  G Bendix; A Bjelle
Journal:  Ann Rheum Dis       Date:  1996-03       Impact factor: 19.103

Review 2.  The gold plated stomach?

Authors:  A S Taha; R D Sturrock
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

Review 3.  Injectable gold for rheumatoid arthritis.

Authors:  P Clark; P Tugwell; K Bennet; C Bombardier; B Shea; G Wells; M E Suarez-Almazor
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 4.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Musculoskeletal disease in the aged. Diagnosis and management.

Authors:  R F Afable; W H Ettinger
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

6.  No relationship between anatomic damage and disability in rheumatoid arthritis (RA). A retrospective assessment.

Authors:  F Salaffi; G F Ferraccioli; W Troise Rioda; M Marini; C Cervini
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

7.  Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps.

Authors:  Ingrid L Bergin; Frank A Witzmann
Journal:  Int J Biomed Nanosci Nanotechnol       Date:  2013

8.  Outcome of second line therapy in rheumatoid arthritis.

Authors:  D R Porter; I McInnes; J Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103

Review 9.  Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.

Authors:  Sam Norton; Bo Fu; David L Scott; Chris Deighton; Deborah P M Symmons; Allan J Wailoo; Jonathan Tosh; Mark Lunt; Rebecca Davies; Adam Young; Suzanne M M Verstappen
Journal:  Semin Arthritis Rheum       Date:  2014-05-09       Impact factor: 5.532

Review 10.  To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology.

Authors:  Jonas Kure Buer
Journal:  Inflammopharmacology       Date:  2017-02-13       Impact factor: 4.473

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.